Skip to Content

Zalicus to Present Data on Novel A2A Agonist Oncology Program at the American Society for Hematology Meeting

- Novel Synergistic Mechanism Discovered for the Treatment of Multiple Myeloma and Other B-cell Cancers Using Zalicus cHTS Technology -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 29, 2010 - Zalicus Inc. (NASDAQ: ZLCS) announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

“These data reinforce the rationale for investigation of A2A agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the Zalicus combination high throughput screening (cHTS™) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application,” commented Mark H.N. Corrigan, M.D., President and CEO of Zalicus Inc. ”Zalicus is continuing to leverage the power of its proprietary cHTS technology through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaborations with Clinical Data, Inc. and Novartis."


  • Sunday, December 5, 2010, 6:00-8:00 p.m., Poster session I: Myeloma – Pathophysiology and Preclinical Studies, excluding Therapy.

    #2990, Poster Board II-870, “ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma”, Rickles, et al, Orange County Convention Center, Hall A3/A4.

ATL313 is a potent and selective A2A agonist being evaluated by Zalicus and PGxHealth, LLC, a division of Clinical Data, Inc., for the treatment of B-cell cancers, including multiple myeloma. ATL313 is also being evaluated by Clinical Data, Inc. and its other collaborators for a number of indications including glaucoma, chronic pain, multiple sclerosis and atherosclerosis.

About Zalicus

Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its A2A agonist program in oncology, its collaboration with PGxHealth, Zalicus' combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the development and regulatory approval of Zalicus's product candidates, the unproven nature of the Zalicus drug discovery technologies, and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

(c) 2010 Zalicus Inc. All rights reserved.

Contact: Zalicus Inc.
Justin Renz, CFO, 617-301-7575
Gina Nugent, 857-753-6562



Posted: November 2010